Preparation methods of capecitabine and intermediate thereof

A technology of capecitabine and methyl, which is applied in the field of preparation of capecitabine and its intermediates, can solve the problems affecting the yield of products, and achieve the effects of avoiding by-products, reducing pollution and high yield

Active Publication Date: 2011-10-12
CHIA TAI TIANQING PHARMA GRP CO LTD +2
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Secondly, because the reduction of sugar sulfonate compounds is often accompanied by the breakage of O-S bonds, there are hydr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation methods of capecitabine and intermediate thereof
  • Preparation methods of capecitabine and intermediate thereof
  • Preparation methods of capecitabine and intermediate thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Preparation of 1-O-methyl-2,3-O-isopropylidene-D-ribofuranose (4):

[0037] D-ribose (3) (20g, 133mmol) was dissolved in methanol (80ml) and acetone (120ml), concentrated hydrochloric acid (2ml) was added, the mixture was refluxed for 3h, allowed to cool, neutralized with solid sodium bicarbonate The pH of the solution was 6-7, the solvent was evaporated under reduced pressure, water (60ml) and ethyl acetate (100ml) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate, the organic phase was washed and dried, filtered, and evaporated to dryness to obtain an oily Material 4 (23.6g, 86.8%) can be directly used in the next reaction.

Embodiment 2

[0039] Preparation of 1-O-methyl-2,3-O-isopropylidene-5-O-p-methylbenzenesulfonyl-D-ribofuranose (5):

[0040] Dissolve the oil 4 (47g, 0.23mol) in dichloromethane (200ml), add triethylamine (56ml), cool to 0-5°C, add p-toluenesulfonyl chloride (62.4g) six times, Each interval is about 10min. After the addition is completed, continue to keep at 5°C, stir for 3h, wash with water (50ml), 1mol / L hydrochloric acid (25ml), saturated aqueous sodium bicarbonate solution (25ml) and water (50ml) successively, evaporate to dryness, and add Ice water, stirred, filtered, washed with water, and dried to obtain solid 5 (60g, 72.7%), mp 80-81°C.

Embodiment 3

[0042] Preparation of 1-O-methyl-2,3-O-isopropylidene-5-deoxy-5-iodo-D-ribofuranose (1):

[0043] Compound 5 (10g, 31.8mmol) was dissolved in acetonitrile (104ml), sodium iodide (12.5g) was added, and the reaction was refluxed for 12h. Let cool, filter, distill off the solvent, add isopropyl ether to stir, filter, wash with isopropyl ether, and evaporate the filtrate to dryness under reduced pressure to give yellow oil 1 (8.5 g, 100%). No need to deal with, directly put into the next reaction.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of capecitabine. The method comprises the following steps: based on D-ribose serving as a starting raw material, carrying out hydroxyl protection, 5-site tosylation, iodine substitution, hypophosphorous acid deiodination and acetylation so as to obtain the key intermediate 12,3-tri-O-acetyl-5-deoxy-beta-D-ribofuranose; carrying out glycosylation on the key intermediate and 5-fluorocytosine; and finally, carrying out N-4 site acylation and deprotection so as to obtain the capecitabine. In the method, a metal catalyst dose not need to be used for participating in reaction, the reaction condition is mild, and the yield is high, thus the method is economical and effective as well as suitable for industrial production on a large scale.

Description

technical field [0001] The invention relates to the technical field of preparation methods of capecitabine and its intermediates. Background technique [0002] Capecitabine is a nucleoside anticancer drug developed by Roche, Switzerland. It was approved by the U.S. Food and Drug Safety Administration in 1998 for the treatment of metastatic colorectal cancer and docetaxel (trade name). : Taisudi, ) combination therapy for the treatment of metastatic breast cancer, which went on the market in my country in 2001. In August 2008, China Food and Drug Administration approved its treatment for advanced gastric cancer. More than 100 countries are currently using capecitabine to treat the above-mentioned cancers. [0003] The chemical name of capecitabine is 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine, and the structure is as follows: [0004] [0005] The synthesis of capecitabine is divided into two parts: [0006] 1. Preparation of 1,2,3-tri-O-acetyl-5-deoxy-β-D-rib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07H19/06C07H15/04C07H1/00
Inventor 陈莉莉岑均达
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap